The Arg389Gly β1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine

被引:14
作者
Leineweber, K
Bruck, H
Temme, T
Heusch, G
Philipp, T
Brodde, OE
机构
[1] Univ Essen Gesamthsch, Sch Med, Dept Nephrol, D-45147 Essen, Germany
[2] Univ Essen Gesamthsch, Sch Med, Dept Pathophysiol, D-45147 Essen, Germany
关键词
beta 1-adrenoceptor polymorphism; exercise; atropine; human heart;
D O I
10.1097/01.fpc.0000184956.16077.93
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In vitro, Arg389Gly beta(1)-adrenoceptor (AR) polymorphism exhibits decreased beta-AR signalling. In vivo, beta(1)-AR-mediated cardiac effects of exercise showed no genotype-dependent differences in Arg389 vs. Gly389 beta(1)-AR subjects. We studied in 16 male subjects homozygous Arg389 or Gly389 beta(1)-AR, whether blockade of parasympathetic activity might unmask genotype-dependence of exercise effects. Subjects were infused with atropine (10 mu g/kg i.v. loading dose followed by continuous i.v. infusion of 0.15 mu g/kg/min throughout exercise-time); 20 min after start of atropine bicycle-exercise in supine position (25, 50, 75 and 100 W for 5 min each) was performed and heart rate, contractility, blood pressure, plasma noradrenaline and plasma-renin activity were assessed. Exercise-evoked increases in all but one parameters were not different between Arg389 and Gly389 beta(1)-AR subjects; only plasma noradrenaline increased slightly more in Gly389 vs. Arg389 beta(1)-AR subjects. In conclusion: It appears to be unlikely that lack of Arg389Gly beta(1)-AR genotype-dependence of exercise-effects can be explained by influences of parasympathetic activity.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 15 条
[1]  
BELZ GG, 1995, EUR J CLIN INVEST, V25, P35
[2]  
Brodde OE, 1999, PHARMACOL REV, V51, P651
[3]   In-vivo studies do not support a major functional role for the Gly389Arg β1-adrenoceptor polymorphism in humans [J].
Büscher, R ;
Belger, H ;
Eilmes, KJ ;
Tellkamp, R ;
Radke, J ;
Dhein, S ;
Hoyer, PF ;
Michel, MC ;
Insel, PA ;
Brodde, OE .
PHARMACOGENETICS, 2001, 11 (03) :199-205
[4]   β-adrenergic receptor polymorphisms:: Cardiovascular disease associations and pharmacogenetics [J].
Johnson, JA ;
Terra, SG .
PHARMACEUTICAL RESEARCH, 2002, 19 (12) :1779-1787
[5]   Autonomic nervous system pharmacogenomics: A progress report [J].
Kirstein, SL ;
Insel, PA .
PHARMACOLOGICAL REVIEWS, 2004, 56 (01) :31-52
[6]   The Arg389Gly β1-adrenoceptor gene polymorphism determines contractile response to catecholamines [J].
La Rosée, K ;
Huntgeburth, M ;
Rosenkranz, S ;
Böhm, M ;
Schnabel, P .
PHARMACOGENETICS, 2004, 14 (11) :711-716
[7]   β-adrenoceptor polymorphisms [J].
Leineweber, K ;
Büscher, R ;
Bruck, H ;
Brodde, OE .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :1-22
[8]   Gly389Arg polymorphism of β1-adenergic receptor is associated with the cardiovascular response to metoprolol [J].
Liu, J ;
Liu, ZQ ;
Tan, ZR ;
Chen, XP ;
Wang, LS ;
Zhou, G ;
Zhou, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (04) :372-379
[9]   Common polymorphisms of β1-adrenoceptor:: identification and rapid screening assay [J].
Maqbool, A ;
Hall, AS ;
Ball, SG ;
Balmforth, AJ .
LANCET, 1999, 353 (9156) :897-897
[10]   A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor [J].
Mason, DA ;
Moore, JD ;
Green, SA ;
Liggett, SB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (18) :12670-12674